Breath Analysis for Early Detection of Malignant Pleural Mesothelioma: Volatile Organic Compounds (VOCs) Determination and Possible Biochemical Pathways.
Malignant Pleural Mesothelioma (MPM)
TD-GC/MS
Volatile Organic Compounds (VOCs)
breath analysis
machine learning
metabolic pathways
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 May 2020
16 May 2020
Historique:
received:
27
03
2020
revised:
17
04
2020
accepted:
08
05
2020
entrez:
21
5
2020
pubmed:
21
5
2020
medline:
21
5
2020
Statut:
epublish
Résumé
Malignant pleural mesothelioma (MPM) is a rare neoplasm, mainly caused by asbestos exposure, with a high mortality rate. The management of patients with MPM is controversial due to a long latency period between exposure and diagnosis and because of non-specific symptoms generally appearing at advanced stage of the disease. Breath analysis, aimed at the identification of diagnostic Volatile Organic Compounds (VOCs) pattern in exhaled breath, is believed to improve early detection of MPM. Therefore, in this study, breath samples from 14 MPM patients and 20 healthy controls (HC) were collected and analyzed by Thermal Desorption-Gas Chromatography-Mass Spectrometry (TD-GC/MS). Nonparametric test allowed to identify the most weighting variables to discriminate between MPM and HC breath samples and multivariate statistics were applied. Considering that MPM is an aggressive neoplasm leading to a late diagnosis and thus the recruitment of patients is very difficult, a promising data mining approach was developed and validated in order to discriminate between MPM patients and healthy controls, even if no large population data are available. Three different machine learning algorithms were applied to perform the classification task with a leave-one-out cross-validation approach, leading to remarkable results (Area Under Curve AUC = 93%). Ten VOCs, such as ketones, alkanes and methylate derivates, as well as hydrocarbons, were able to discriminate between MPM patients and healthy controls and for each compound which resulted diagnostic for MPM, the metabolic pathway was studied in order to identify the link between VOC and the neoplasm. Moreover, five breath samples from asymptomatic asbestos-exposed persons (AEx) were exploratively analyzed, processed and tested by the validated statistical method as blinded samples in order to evaluate the performance for the early recognition of patients affected by MPM among asbestos-exposed persons. Good agreement was found between the information obtained by gold-standard diagnostic methods such as computed tomography CT and model output.
Identifiants
pubmed: 32429446
pii: cancers12051262
doi: 10.3390/cancers12051262
pmc: PMC7280981
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Chem Biol Interact. 1980 Dec;33(1):1-17
pubmed: 7438288
Mol Pharmacol. 1978 Sep;14(5):920-9
pubmed: 714029
J Thorac Oncol. 2009 May;4(5):620-8
pubmed: 19357540
Oncotarget. 2017 May 17;8(32):53751-53762
pubmed: 28881848
J Hazard Mater. 2018 Feb 15;344:981-993
pubmed: 29207357
J Lab Clin Med. 1992 Jun;119(6):598-620
pubmed: 1593209
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Chem Biol Interact. 1983 Nov;47(2):195-212
pubmed: 6652808
Am J Ind Med. 2015 May;58(5):473-82
pubmed: 25754500
Free Radic Biol Med. 1999 Dec;27(11-12):1182-92
pubmed: 10641709
Anal Chem. 2012 Jan 3;84(1):379-85
pubmed: 22103598
Int J Cancer. 2015 Oct 1;137(7):1539-48
pubmed: 25784292
Clin Chem Lab Med. 2009;47(5):550-60
pubmed: 19397483
Anal Biochem. 1993 May 1;210(2):268-76
pubmed: 8512062
J Breath Res. 2019 Apr 24;13(3):034002
pubmed: 30822771
Transl Pediatr. 2015 Oct;4(4):304-17
pubmed: 26835392
Crit Rev Oncol Hematol. 2016 Aug;104:9-20
pubmed: 27286698
ACS Omega. 2018 May 31;3(5):5131-5140
pubmed: 30023907
J Natl Cancer Inst. 2013 Feb 20;105(4):293-301
pubmed: 23355760
Anal Bioanal Chem. 2010 Dec;398(7-8):3043-50
pubmed: 20924566
Cancers (Basel). 2019 Jun 14;11(6):
pubmed: 31207975
Cell Death Dis. 2016 May 26;7:e2237
pubmed: 27228352
Cancer. 2007 Aug 15;110(4):835-44
pubmed: 17599760
Eur Respir J. 2012 Aug;40(2):448-54
pubmed: 22183490
Br J Cancer. 2010 Aug 10;103(4):542-51
pubmed: 20648015
Scand J Public Health. 2015 Dec;43(8):875-81
pubmed: 26194352
Free Radic Res. 1994 May;20(5):333-7
pubmed: 8069391
Sci Rep. 2017 Sep 11;7(1):11087
pubmed: 28894173
Lung Cancer. 2012 Mar;75(3):326-31
pubmed: 21924516
Acta Biomed. 2008;79 Suppl 1:64-72
pubmed: 18924311
Oncotarget. 2017 Sep 27;8(53):91593-91602
pubmed: 29207669
Biochem J. 2009 Jan 1;417(1):1-13
pubmed: 19061483
Anticancer Res. 2009 Jan;29(1):419-26
pubmed: 19331181
Metabolites. 2019 Mar 18;9(3):
pubmed: 30889835
J Thorac Oncol. 2016 Jun;11(6):827-37
pubmed: 26968885
PLoS One. 2013 Apr 23;8(4):e61253
pubmed: 23626673
Clin Chem. 1988 Aug;34(8):1613-8
pubmed: 3042190
J Breath Res. 2014 Mar;8(1):016003
pubmed: 24566039
Lancet Oncol. 2013 Jun;14(7):576-8
pubmed: 23725699
Occup Environ Med. 2017 Nov;74(11):838-846
pubmed: 28935666
iScience. 2019 Jan 25;11:178-188
pubmed: 30612036
Thorax. 2007 Jul;62(7):565-8
pubmed: 17327260
Sci Total Environ. 2012 Mar 1;419:225-32
pubmed: 22285084
Lung. 2014 Feb;192(1):197-203
pubmed: 24170217
BMC Cancer. 2009 Sep 29;9:348
pubmed: 19788722
Neuroimage. 2019 Jul 15;195:150-164
pubmed: 30951846
Regul Toxicol Pharmacol. 2015 Aug;72(3):615-29
pubmed: 25985714
Crit Rev Toxicol. 2008;38 Suppl 1:49-73
pubmed: 18686078
Clin Chim Acta. 2004 Sep;347(1-2):25-39
pubmed: 15313139
J Clin Invest. 2015 Feb;125(2):687-98
pubmed: 25607840
Mol Cancer. 2009 Jun 26;8:41
pubmed: 19558692
Eur Respir J. 2017 Dec 21;50(6):
pubmed: 29269578
Transl Lung Cancer Res. 2018 Oct;7(5):520-536
pubmed: 30450290
Cell. 2017 Oct 5;171(2):358-371.e9
pubmed: 28985563
J Breath Res. 2016 Sep 26;10(4):046001
pubmed: 27669062
Occup Environ Med. 2016 Mar;73(3):187-94
pubmed: 26800709
Cell. 2016 Feb 11;164(4):681-94
pubmed: 26853473
Cancer Causes Control. 1999 Feb;10(1):51-7
pubmed: 10334642
Chem Rev. 2012 Nov 14;112(11):5949-66
pubmed: 22991938